Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home
Status: | Recruiting |
---|---|
Conditions: | Diabetes, Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 2 - 80 |
Updated: | 3/29/2019 |
Start Date: | May 25, 2017 |
End Date: | December 2021 |
Contact: | Thomas Troub |
Email: | thomas.troub@medtronic.com |
Phone: | (818) 576-3142 |
Multi-center, Randomized, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed
Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A
diverse population of patients with type 1 diabetes will be studied. The study population
will have a large range for duration of diabetes and glycemic control, as measured by
glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior
diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous
Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A
diverse population of patients with type 1 diabetes will be studied. The study population
will have a large range for duration of diabetes and glycemic control, as measured by
glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior
diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous
Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
This is a 6 month, multi-center, randomized, parallel, adaptive study in type 1 diabetes with
a 6 month continuation period. The study will have three periods:
1. Run-in Period: The run-in period can be up to 60 days during which time a blinded CGM
sensor will be worn for two weeks.
2. Study Period: There will be a 6 month randomized study period with two arms: The HCL
system and Control.
3. Continuation Period: There will be a 6 month continuation period during which time all
subjects will use the HCL system with Auto Mode.
Up to 1500 subjects will be enrolled in order to have 1120 subjects complete the study. Up to
70 investigational Centers in the US, Europe and Canada will be enrolled.
a 6 month continuation period. The study will have three periods:
1. Run-in Period: The run-in period can be up to 60 days during which time a blinded CGM
sensor will be worn for two weeks.
2. Study Period: There will be a 6 month randomized study period with two arms: The HCL
system and Control.
3. Continuation Period: There will be a 6 month continuation period during which time all
subjects will use the HCL system with Auto Mode.
Up to 1500 subjects will be enrolled in order to have 1120 subjects complete the study. Up to
70 investigational Centers in the US, Europe and Canada will be enrolled.
Inclusion Criteria
1. Subject is age 2-80 years at time of screening
1. US and Canada: Subjects 2-6 years of age will be allowed to enroll in the post
approval study, once DMC has reviewed data from 10 subjects age 2-4 years who
have completed participation in the study period of the CEP302 study and has
given approval to enroll
2. Europe: Only subjects ≥7 years of age are allowed to enroll in the post-market
study.
2. Subjects who are 2-21 years are determined by the investigator to have the
appropriate, requisite support (family, caregiver or social network) to successfully
participate in this study
3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of equal to
or greater than 8 units/day
4. Subjects who are determined by the investigator to be psychologically sound in order
to successfully participate in this study
5. Subject has been diagnosed with type 1 diabetes for at least three months Note:
Determination of classification for diabetes will be based on American Diabetes
Association Clinical Practice Guidelines accounting for several patient
characteristics such as: age of onset, patient's weight or BMI, history of diabetic
ketoacidosis, history of therapy management, if available in the medical records.
6. Subject must be on one of the following management therapies:
1. Multiple daily injections defined by use of rapid analogue with meals and
approved long acting analogue (e.g. detemir or glargine) with or without CGM
2. Insulin pump therapy with or without CGM
7. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
8. Subject is willing to perform required study procedures
9. Subject is willing to wear the system continuously throughout the study for at least
80% of the time.
10. Subject is willing to upload data at least weekly from the study pump/meter, must have
Internet access and a computer system that meets the requirements for uploading the
study pump/meter for data collection
11. Subject must be willing to use the study glucose meter system (i.e. along with study
meter strips).
12. If subject has celiac disease, it has been adequately treated as determined by the
investigator
13. Subject with the diagnosis of myocardial infarction, unstable angina, coronary artery
bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular
accident, angina, congestive heart failure, ventricular rhythm disturbances or
thromboembolic disease, within 1 year of screening, will be included in the study with
the consent of the Investigator
14. Subject is willing to take one of the following insulins and can financially afford to
use either of the 2 insulin preparations throughout the course of the study (i.e.
co-payments for insulin with insurance or able to pay full amount)
1. Humalog® (insulin lispro injection)
2. NovoLog® (insulin aspart)
Exclusion Criteria:
1. Subject participated in any Closed Loop study in the past.
2. Subject is unable to tolerate tape adhesive in the area of sensor placement
3. Subject has any unresolved adverse skin condition in the area of sensor placement
(e.g., psoriasis, rash, Staphylococcus infection) or area of infusion set placement
4. Women of child-bearing potential who have a positive pregnancy test at screening or
plan to become pregnant during the course of the study
5. Subject is being treated for hyperthyroidism at time of screening
6. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone
(TSH) at time of screening visit
7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time
of screening visit, or plans to take any oral, injectable, or IV glucocorticoids
during the course of the study.
8. Subject is actively participating in an investigational study (drug or device) wherein
he/she has received treatment from an investigational study drug or investigational
study device in the last 2 weeks
9. Subject is currently abusing illicit drugs or marijuana
10. Subject is currently abusing prescription drugs
11. Subject is currently abusing alcohol
12. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides,
DPP-4 inhibitors or sulfonylureas at time of screening
13. Subject has a history of visual impairment which would not allow subject to
participate in the study and perform all study procedures safely, as determined by the
investigator
14. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell
transfusion or erythropoietin within 3 months prior to time of screening
15. Subject plans to receive red blood cell transfusion or erythropoietin over the course
of study participation
16. Subject diagnosed with current moderate to severe eating disorder such as anorexia or
bulimia
17. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting
in chronic anemia
18. Subjects who are currently being actively treated for cancer.
19. Subject who is designated as a research staff member for this study
We found this trial at
23
sites
750 East Adams Street
Syracuse, New York 13210
Syracuse, New York 13210
Principal Investigator: Ruth Weinstock, MD
Phone: 315-464-9006
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Seattle, Washington 98104
(206) 543-2100
![Univ of Washington](/wp-content/uploads/logos/univ-of-washington.jpg)
Principal Investigator: Irl Hirsch, MD
Phone: 206-598-1262
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
![University of Michigan](/wp-content/uploads/logos/university-of-michigan.jpg)
Principal Investigator: Rodica Pop-Busui, MD
Phone: 734-936-8065
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Atlanta, Georgia 30309
Principal Investigator: Bruce Bode, MD
Phone: 404-355-4393
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aurora, Colorado 80010
Principal Investigator: Robert Slover, MD
Phone: 303-724-7514
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Austin, Texas 78731
Principal Investigator: Luis Casaubon, MD
Phone: 512-334-3505
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bloomfield Hills, Michigan 48302
Principal Investigator: George Grunberger, MD
Phone: 248-335-7740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brescia, 25028
Principal Investigator: Angela Girelli, MD
Phone: +39 030 3995514
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Houston, Texas 77030
Principal Investigator: Maria Redondo, MD
Phone: 832-824-0251
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Idaho Falls, Idaho 93404
Principal Investigator: David Liljenquist, MD
Phone: 208-522-6005
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
La Jolla, California 92037
Principal Investigator: Athena Philis-Tsimikas, MD
Phone: 858-717-3267
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3800 Park Nicollet Boulevard
Minneapolis, Minnesota 55416
Minneapolis, Minnesota 55416
Principal Investigator: Amy Criego, MD
Phone: 952-993-3545
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Minneapolis, Minnesota 55416
Principal Investigator: Anders Carlson, MD
Phone: 952-993-3545
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
New Haven, Connecticut 06520
Principal Investigator: Stuart Weinzimer, MD
Phone: 203-737-3595
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Palo Alto, California 94304
Principal Investigator: Bruce Buckingham, MD
Phone: 650-736-8142
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Renton, Washington 98057
Principal Investigator: Ronald Brazg, MD
Phone: 425-251-1720
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Roswell, Georgia 30076
Principal Investigator: John Reed, MD
Phone: 678-878-4750
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Saint Louis, Missouri 63110
Principal Investigator: Janet McGill, MD
Phone: 314-362-8608
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Sioux Falls, South Dakota 57104
Principal Investigator: Kurt Griffin, MD
Phone: 605-328-8742
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Torrance, California 90505
Principal Investigator: Kevin Kaiserman, MD
Phone: 310-962-1808
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Walnut creek, California 94598
Principal Investigator: Mark Christiansen, MD
Phone: 925-930-7267
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)